Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Connecticut Children's Medical Center |
---|---|
Information provided by: | Connecticut Children's Medical Center |
ClinicalTrials.gov Identifier: | NCT00279786 |
Beta(2)-adrenergic receptor (BAR) agonists are the most important group of drugs used in the treatment of asthma. In children unresponsive to inhaled BAR agonist therapy, higher dose systemic BAR agonist therapy is frequently the next step in treatment. Despite the widespread use of intravenous BAR agonist therapy for pediatric status asthmaticus, there is controversy regarding the efficacy of this therapy. A number of studies have established that genetic variations of the BAR have important effects in modulating responses to BAR agonist therapy for asthma. In particular, changes in amino acid position 16 of the BAR gene are thought to be the most functionally important. Patients encoded for two glycine amino acids, rather than arginine, at this position appear to have more severe asthma and to respond differently to acute BAR agonist therapy.
Our hypothesis is that genotypic differences may contribute to poor response to acute BAR agonist treatment. We propose to conduct a prospective observational study to determine the influence of a patient's BAR genotype on the response to acute BAR agonist therapy.
Our specific hypothesis is that children with genetic polymorphisms of the gene encoding the BAR will have a decreased response to acute high-dose continuous BAR therapy (both inhaled and intravenous) compared to other children.
Our primary outcome is ICU length of stay. Secondary outcomes are
Condition | Intervention | Phase |
---|---|---|
Status Asthmaticus |
Procedure: Blood draw |
Phase IV |
Study Type: | Observational |
Study Design: | Cohort |
Official Title: | B2-Adrenergic Receptor Polymorphisms: Implications For The Treatment Of Status Asthmaticus In Children |
Estimated Enrollment: | 90 |
Study Start Date: | December 2005 |
Estimated Study Completion Date: | April 2009 |
This study has both a prospective and a retrospective arm. In the retrospective arm, patients with a history of admission to the ICU with a severe asthma exacerbation are contacted by phone and mail and DNA samples are obtained via saliva. In the prospective arm, patients admitted to the ICU are contacted prospectively and DNA is obtained either via saliva or blood.
Ages Eligible for Study: | 2 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Children admitted to the ICU with severe asthma exacerbations
Inclusion Criteria:
Exclusion Criteria:
Contact: Christopher Carroll, MD | (860) 545-9805 | ccarroll@ccmckids.org |
United States, Connecticut | |
CT Children's Medical Center | Recruiting |
Hartford, Connecticut, United States, 06106 |
Principal Investigator: | Christopher Carroll, MD | CT Children's Medical Center |
Responsible Party: | Connecticut Children's Medical Center ( Christopher Carroll, MD ) |
Study ID Numbers: | 06-001 |
Study First Received: | January 18, 2006 |
Last Updated: | December 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00279786 |
Health Authority: | United States: Institutional Review Board |
pediatric |
Hypersensitivity Respiratory Tract Diseases Status Asthmaticus |
Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity |
Immune System Diseases Bronchial Diseases |